According to GuruFocus Insider Data, the recent CFO buys were: Blue Apron Holdings Inc. (APRN, Financial), RiceBran Technologies (RIBT, Financial) and Aeglea BioTherapeutics Inc. (AGLE, Financial).
Blue Apron Holdings Inc.: President, CEO, CFO and Treasurer Brad Dickerson bought 180,000 shares
President, CEO, CFO and Treasurer Brad Dickerson bought 180,000 shares for $3.93 per share on Dec. 13. The stock price has increased by 7.38%. Blue Apron Holdings Inc. has a market cap of $802.390 million and its shares were traded around $4.22. The company has a P/S ratio of 0.55.
SVP and Gen. Mgr. Consumer Products Timothy J Smith bought 25,000 shares for $3.89 per share on Dec. 11. The stock price has increased by 8.48%. Sr VP of Op and Fulfillment Pablo Cussatti sold 2,209 shares for $3.05 per share on Nov. 28. The stock price has increased by 38.36%. 10% Owner Round Capital IV Partner First sold 65,728 shares for $3.03 per share on Nov. 22. The stock price has increased by 39.27%.
RiceBran Technologies: CFO and EVP Brent Robert Rystrom bought 79,423 shares
CFO and EVP Brent Robert Rystrom bought 5,000 shares for $1.41 per share on Dec. 13. Since then, the stock price has increased by 3.55%. RiceBran Technologies has a market cap of $24.660 million and its shares were traded around $1.46. The company has a P/S ratio of 0.35.
RiceBran Technologies announced its 2017 second-quarter results with revenues of $3.45 million and gross profit of $1.14 million; the net income was $3.3 million. The 2016 total revenue was $39.41 million, a 1% decrease from the 2015 total revenue. The 2016 gross profit was $7.97 million, a 1% decrease from the 2015 gross profit. The 2016 net loss was $8.53 million.
CEO and President Robert D Smith bought 3,500 shares for $1.46 per share on Dec. 12. Since then, the stock price has not changed. President of USA Ingredients Michael Goose bought 2,500 shares for $1.44 per share on Dec. 14. Since then, the stock price has increased by 1.39%. Director Henk Hoogenkamp bought 6,000 shares for $1.46 per share on Dec. 12. Since then, the stock price has not changed.
Aeglea BioTherapeutics Inc.: CFO and VP Charles N York II bought 25,959 shares
CFO and VP Charles N York II bought 25,959 shares for $4.48 per share on Dec. 05. Since then, the stock price has increased by 8.71%. Aeglea Biotherapeutics Inc. has a market cap of $81.080 million and its shares were traded around $4.87. The company has a P/S ratio of 14.00.
Aeglea Biotherapeutics announced its 2017 third-quarter results with revenues and gross profit of $1.26 million; the net loss was $7.87 million. The 2016 total revenue and gross profit was $4.63 million, a 24% decrease from the 2015 total revenue. The 2016 net loss was $21.70 million.
Interim CEO Anthony G. Quinn bought 8,288 shares for $4.96 per share on Dec. 08. Since then, the stock price has decreased by 1.81%. Director Anthony G. Quinn bought 17,121 shares for $4.86 per share on Dec. 05. Since then, the stock price has increased by 0.21%.
Disclosure: none
